Skip to content

Study · Not a test of the peptide alone · 2021

2 results

Furan warheads for covalent trapping of weak protein-protein interactions: cross-linking of thymosin β4 to actin.

Miret-Casals L , Vannecke W , Hoogewijs K , Arauz-Garofalo G , Gay M , Díaz-Lobo M , Vilaseca M , Ampe C , Van Troys M , Madder A

Chemical communications (Cambridge, England)25 May 2021Cited by 10 (Europe PMC)

PMID34036992 (opens in a new tab)DOI10.1039/d1cc01731d (opens in a new tab)PepBankPUB-34036992
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 01LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cell-free)Mechanism

    Cross-linking of furan-armed Tβ4 to actin identified lysine as a target of the furan warhead.

    In plain wordsIn lab tests, a chemical group on modified Tβ4 linked to actin at lysine residues.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableResidues cross-linked by the furan warhead
    Study

    n: not reported in source

    actin and furan-armed Tβ4 variants
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    The identified cross-linked residues demonstrate that lysine is a target for the furan warhead.
    1 context sentence
    Summary · context
    We describe furan as a triggerable 'warhead' for site-specific cross-linking using the actin and thymosin β4 (Tβ4)-complex as model of a weak and dynamic protein-protein interaction (PPI) with known 3D structure and with application potential in disease contexts.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 02LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cell-free)Mechanism

    In vitro validation of covalently acting furan-armed Tβ4 variants provided initial proof for furan technology in covalent drug design targeting lysines.

    In plain wordsIn lab tests, modified Tβ4 variants bound actin covalently, which gives first proof for this method.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableIn vitro validation of covalent furan-armed Tβ4 variants
    Study

    n: not reported in source

    actin and furan-armed Tβ4 variants
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    The presented in vitro validation of covalently acting 'furan-armed' Tβ4-variants provides initial proof to further exploit furan-technology for covalent drug design targeting lysines.
    1 context sentence
    Summary · context
    We describe furan as a triggerable 'warhead' for site-specific cross-linking using the actin and thymosin β4 (Tβ4)-complex as model of a weak and dynamic protein-protein interaction (PPI) with known 3D structure and with application potential in disease contexts.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.